Stuart B. Parker
Stuart B. Parker's purchase track record
How the stock did after each of Stuart B. Parker's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/10/2025 | KMPR | $921K | -6.7% | -14.8% | +8.5% |
| 11/20/2023 | KMPR | $414K | +43.5% | +44.9% | +16.7% |
| 8/4/2022 | KMPR | $213K | +17.1% | +34.5% | +0.7% |
| 12/9/2021 | HQY | $1.07M | +27.6% | +50.0% | -13.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Kemper Q2 earnings reviewed alongside peers. Kemper Corporation's second-quarter results are being analyzed in comparison to other multi-line insurance companies. This review helps investors understand how KMPR performed relative to industry standards. The stock currently trades with a dividend yield of 2.91%, while analysts maintain an average price target of $36.33.
Transaction History
| HQY | ▲ Buy | Grant | 2,877 | $0 | 6/25/2026 | View on chart |
| KMPR | ▲ Buy | Grant | 4,730 | $155K | 5/6/2026 | View on chart |
| HQY | ▲ Buy | Grant | 1,263 | $0 | 2/2/2026 | View on chart |
| KMPR | ▲ Buy | Open Market | 25,000 | $921K | 11/10/2025 | View on chart |
| HQY | ▲ Buy | Grant | 2,003 | $0 | 6/26/2025 | View on chart |
| KMPR | ▲ Buy | Grant | 2,435 | $150K | 5/7/2025 | View on chart |
| HQY | ▲ Buy | Grant | 771 | $0 | 2/3/2025 | View on chart |
| HQY | ▼ Sell | Open Market | 24,272 | $2.3M | 12/12/2024 | View on chart |
| HQY | ▼ Sell | Open Market | 728 | $71K | 12/12/2024 | View on chart |
| KMPR | ▼ Sell | Open Market | 30,000 | $1.9M | 8/21/2024 | View on chart |
| HQY | ▲ Buy | Grant | 2,543 | $0 | 7/5/2024 | View on chart |
| KMPR | ▲ Buy | Grant | 2,565 | $0 | 5/1/2024 | View on chart |
| HQY | ▲ Buy | Grant | 1,058 | $0 | 2/1/2024 | View on chart |
| KMPR | ▲ Buy | Open Market | 10,000 | $414K | 11/20/2023 | View on chart |
| HQY | ▲ Buy | Grant | 3,164 | $0 | 6/22/2023 | View on chart |
| KMPR | ▲ Buy | Grant | 2,933 | $0 | 5/3/2023 | View on chart |
| HQY | ▲ Buy | Grant | 1,102 | $0 | 2/1/2023 | View on chart |
| KMPR | ▲ Buy | Open Market | 5,000 | $213K | 8/4/2022 | View on chart |
| HQY | ▲ Buy | Grant | 2,996 | $0 | 6/23/2022 | View on chart |
| KMPR | ▲ Buy | Grant | 2,525 | $0 | 5/4/2022 | View on chart |
| HQY | ▲ Buy | Grant | 727 | $0 | 2/1/2022 | View on chart |
| HQY | ▲ Buy | Grant | 1,212 | $0 | 2/1/2022 | View on chart |
| HQY | ▲ Buy | Open Market | 25,000 | $1.1M | 12/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
HealthEquity Appoints Moody's CFO to Board Amid AI Cash Concerns
HealthEquity has appointed Noémie Heuland, CFO of Moody's, to its board of directors. This governance move comes as market commentary highlights concerns regarding the company's cash position in the context of AI adoption. The stock is currently trading near its 52-week low, with an average analyst target price of $119.33.
HealthEquity Appoints Moody's CFO to Board Amid AI Cash Concerns. HealthEquity has appointed Noémie Heuland, CFO of Moody's, to its board of directors. This governance move comes as market commentary highlights concerns regarding the company's cash position in the context of AI adoption. The stock is currently trading near its 52-week low, with an average analyst target price of $119.33.